Cellectar Biosciences and the Wisconsin Alumni Research Foundation announced it new license agreement for intellectual property rights covering the method of use for the company’s compound, CLR 131, in multiple…

The U.S. Patent and Trademark Office has awarded Cellectar Biosciences a patent that covers the method of use for CLR 1603 to treat breast, lung, colorectal and prostate cancers as…

Cellectar Biosciences announced recently a clinical benefit rate of 80 percent from its Phase I clinical study of CLR 131 in patients with relapsed or refractory multiple myeloma. “The efficacy…

Cellectar Biosciences today announced the effective price of $1.50 per share of common stock of an underwritten public offering to raise approximately $8 million. According to a release, Cellectar will use…

Cellectar Biosciences’ CLR 131, its lead therapeutic compound, will be used in a University of Wisconsin study of neck and head cancers, the organization announced today. According to a release,…

Cellectar Biosciences announced today it is the recipient of the second phase of a National Cancer Institute Fast-Track SBIR contract worth $2 million. According to a release, the money will be used to…

The U.S. Patent and Trademark Office has awarded Cellectar Biosciences a patent that covers CLR 1603, a phospholipid ether-paclitaxel conjugate, the company announced recently. “This first issued patent under our CLR CTX…

Cellectar Biosciences‘ public offering raised $8 million, the company announced today. “We are pleased with the results of this offering, including the underwriter’s exercise of their full over-allotment option,” Cellectar…

Cellectar Biosciences announced today it is the recipient of a $2.3 million Fast-Track SBIR grant. According to a release, the money from the National Cancer Institute will help fund development of the…

Cellectar Biosciences today announced it is looking to raise $3.3 million through Wednesday by pricing common stock at $2.20 per share. According to a release, the company looks to use the…